Current Therapies and Future Horizons in Cardiac Amyloidosis Treatment

Area of Science:

• Cardiology
• Nephrology
• Neurology

Background:

• Cardiac amyloidosis (CA) involves protein misfolding and deposition, causing organ dysfunction.
• Transthyretin amyloid (ATTR) and immunoglobulin light chain amyloid are the most prevalent CA subtypes.

Purpose of the Study:

• To review the current standard-of-care for cardiac amyloidosis therapy.
• To outline the evolving scientific landscape and therapeutic interventions for CA.

Main Methods:

• Review of current scientific literature and ongoing clinical trials.
• Analysis of therapeutic challenges and emerging treatment modalities for CA.

Main Results:

• Over 100 clinical trials are underway, highlighting the urgent need for advanced CA therapies.
• Tafamidis, an ATTR-stabilizer, is the first approved drug, with silencers, antibodies, and gene therapy in late-stage trials.
• CA complicates heart failure treatment, causing poor medication tolerance and challenges in managing comorbidities like atrial fibrillation and valvular disease.

Conclusions:

• Managing cardiac amyloidosis presents a critical challenge for future heart failure care.
• The therapeutic landscape for CA is rapidly advancing with novel drug classes and genetic therapies.
• Optimizing CA treatment requires addressing medication tolerance and comorbidity management.